Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H30O |
| Molecular Weight | 286.4516 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=C/CO)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C
InChI
InChIKey=FPIPGXGPPPQFEQ-OVSJKPMPSA-N
InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8801161
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8801161
Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30972178 |
|||
Target ID: O95237 Gene ID: 9227.0 Gene Symbol: LRAT Target Organism: Homo sapiens (Human) |
|||
Target ID: Q96NR8 Gene ID: 145226.0 Gene Symbol: RDH12 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB00162 |
|||
Target ID: Q92781 Gene ID: 5959.0 Gene Symbol: RDH5 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB00162 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | AQUASOL A Approved UseUsed to treat and prevent symptoms of vitamin A deficiency such as xerophthalmia and night blindness. Used as a dietary supplement to prevent vitamin A deficiency in patients with GI diseases (e.g., malabsorption syndromes) and those with abnormal storage and transport of vitamin A (e.g., abetalipoproteinemia, protein deficiency, diabetes mellitus, hyperthyroidism, fever, liver disease, cystic fibrosis with hepatic involvement). Launch Date1949 |
|||
| Palliative | AQUASOL A Approved UseChildren with severe measles have been found to have low serum concentrations of vitamin A; WHO and AAP recommend that vitamin A supplements be given to all children with acute measles, regardless of their country of residence. Launch Date1949 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Vitamin A abuse: development of cirrhosis despite cessation of vitamin A. A six-year clinical and histopathologic follow-up. | 1992 Dec |
|
| Use of vitamin supplements and cataract: the Blue Mountains Eye Study. | 2001 Jul |
|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
| The anemia of vitamin A deficiency: epidemiology and pathogenesis. | 2002 Apr |
|
| DNA microarray technology reveals similar gene expression patterns in rats with vitamin a deficiency and chemically induced colitis. | 2002 Aug |
|
| [Treatment of acne with consequences -- pseudotumor cerebri due to hypervitaminosis A]. | 2002 Jan 9 |
|
| Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. | 2002 Nov |
|
| [Basic aspects and measurement of the antioxidant vitamins A and E]. | 2002 Sep |
|
| PPARbeta regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. | 2003 Feb |
|
| Vitamin A deficiency leads to increased cell proliferation in olfactory epithelium of mature rats. | 2003 Mar |
|
| Ocular side effects from herbal medicines and nutritional supplements. | 2004 Oct |
|
| Differential effects of vitamin A on fetal lung growth and diaphragmatic formation in nitrofen-induced rat model. | 2005 |
|
| Alcohol, vitamin A, and cancer. | 2005 Apr |
|
| What is the safe dose of vitamin A in children with measles? | 2005 Apr |
|
| Retinoid receptor mRNA expression profiles in human bladder cancer specimens. | 2005 Apr |
|
| Fortification of maize meal improved the nutritional status of 1-3-year-old African children. | 2005 Aug |
|
| Effects of prenatal vitamins A, E, and C on the hypoplastic hearts of fetal rats with diaphragmatic hernia. | 2005 Aug |
|
| Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. | 2005 Jul 4 |
|
| Effect of vitamin A content in cafeteria diet on the expression of nuclear receptors in rat subcutaneous adipose tissue. | 2005 Jun |
|
| Vitamin a deficiency and anaemia in young children living in a malaria endemic district of western Kenya. | 2005 Jun |
|
| Vitamin A deficiency induces prooxidant environment and inflammation in rat aorta. | 2005 Jun |
|
| Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. | 2005 Oct |
|
| Comparison of indices of vitamin A status in children with chronic liver disease. | 2005 Oct |
|
| Vitamin A regulation of BMP4 expression in the male germ line. | 2005 Oct 1 |
|
| Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. | 2005 Sep 20 |
|
| Hypervitaminosis A resulting in DNA aberration in fetal transgenic mice (Muta Mouse). | 2005 Sep 5 |
|
| Effects of nitrofen and vitamins A, C and E on maturation of cultured human H441 pneumocytes. | 2006 |
|
| Vitamin A improves Pax3 expression that is decreased in the heart of rats with experimental diaphragmatic hernia. | 2006 Feb |
|
| The acute and chronic toxic effects of vitamin A. | 2006 Feb |
|
| Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. | 2006 Jan |
Patents
Sample Use Guides
The role of vitamin A (2.72 μM/7 ml culture), a naturally occurring antioxidant upon arsenic-induced genotoxicity; with respect to chromosomal aberrations (structural and numerical) and micronuclei. Whole blood cultures set for 72 h were exposed to test chemicals for a period of 24 h ahead of harvesting. Arsenic concentrations tested in the present study are 0.36, 0.72 and 1.4 μM/7 ml culture. Mitomycin C (MMC), the direct acting mutagen was used as positive control.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR01AX02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
20947-8
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
14905-4
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-VATC |
QS01XA02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
NCI_THESAURUS |
C68299
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
NCI_THESAURUS |
C938
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-VATC |
QD10AD02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
20948-6
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
DSLD |
3441 (Number of products:6)
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-ATC |
S01XA02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-ATC |
A11CA01
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/17/1895
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
20946-0
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
87673-0
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
2923-1
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-ATC |
D10AD02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-ATC |
R01AX02
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
WHO-VATC |
QA11CA01
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
||
|
LOINC |
2922-3
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2831
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
DTXSID3023556
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
45479
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
68-26-8
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
1367187
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
445354
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
DB00162
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
815
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL986
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
50211
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
2243
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
100000076424
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
RETINOL
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
G2SH0XKK91
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
17336
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
200-683-7
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
SUB16102MIG
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
C68302
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
G2SH0XKK91
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
122759
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | |||
|
m11481
Created by
admin on Mon Mar 31 18:12:19 GMT 2025 , Edited by admin on Mon Mar 31 18:12:19 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY